MLYS stock news · Mineralys Therapeutics
Get alerts for MLYS
Follow Mineralys Therapeutics (MLYS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MLYSFree on the App Store and Google Play, or on the web.
Mineralys Therapeutics shared new results showing lorundrostat significantly lowered blood pressure and was well-tolerated.
Good for MLYSMineralys Therapeutics said lorundrostat cut systolic blood pressure by 17.8 mmHg over 48 weeks. 56% of participants had systolic blood pressure below 130 mmHg, supporting its drug program.
Mineralys Therapeutics shared new results showing lorundrostat significantly lowered blood pressure in its latest trial.
Good for MLYSMineralys reported a 17.8 mmHg blood-pressure drop over 48 weeks, and 56% of participants reached below 130 mmHg. This is encouraging evidence for its drug candidate, though it remains unapproved.
Mineralys Therapeutics added new board members and shared details about their pay.
NeutralMLYS added 2 independent directors to its board and assigned them committee roles. Their stock awards add compensation and could add shares, but the filing reports no change to company plans or results.